(15352506), C. A., (15352509), A. B., (15352512), R. S., (15352515), M. G., (15352518), A. C., (15086287), D. R., . . . (15352566), C. C. (2025). Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer.
Chicago Style (17th ed.) Citation(15352506), Carlotta Antoniotti, et al. Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI Plus Bevacizumab in Metastatic Colorectal Cancer. 2025.
MLA (9th ed.) Citation(15352506), Carlotta Antoniotti, et al. Supplementary Figure S2 from An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI Plus Bevacizumab in Metastatic Colorectal Cancer. 2025.